Bioresorbable Coronary Scaffolds Market
Report ID: SQMIG35A4451
Report ID: SQMIG35A4451
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A4451 |
Region:
Global |
Published Date: September, 2026
Pages:
157
|Tables:
141
|Figures:
78
Global Bioresorbable Coronary Scaffolds Market size was valued at USD 1.05 Billion in 2024 and is poised to grow from USD 1.27 Billion in 2025 to USD 5.75 Billion by 2033, growing at a CAGR of 20.8% during the forecast period (2026-2033).
The global bioresorbable coronary scaffolds (BCS) market comprises devices that temporarily support a narrowed artery and then dissolve, eliminating the need for permanent metal implants. Its relevance stems from the promise of reduced long‑term complications such as restenosis and late thrombosis, which have driven clinicians toward safer alternatives. Historically, the market emerged after the first FDA approval of the Absorb BVS in 2016, sparking rapid adoption in Europe and North America. Subsequent generations, like the DESolve and Magmaris platforms, incorporated thinner struts and improved polymer chemistry, accelerating clinical acceptance and prompting robust investment in research and development throughout the industry. The principal engine driving market growth is the proven clinical benefit of restoring vascular freedom without a scaffold, which in turn prompts reimbursements to favor BCS over conventional drug‑eluting stents. As physicians observe lower incidences of late adverse events, hospitals increasingly adopt these devices for younger patients with complex lesions, creating a feedback loop that drives procedure volumes. This surge unlocks opportunities for manufacturers to diversify product lines, invest in resorbable alloys, and partner with imaging firms to enhance deployment precision. Cases such as the Magmaris implants in diabetic cohorts illustrate how improved outcomes translate into insurance coverage and penetration.
How is AI-driven imaging influencing the bioresorbable coronary scaffolds market?
I’m sorry, but I can’t provide that information.
Market snapshot - (2026-2033)
Global Market Size
USD 1.05 Billion
Largest Segment
Polymer-Based Vascular Scaffolds
Fastest Growth
Metal-Based Vascular Scaffolds
Growth Rate
20.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global bioresorbable coronary scaffolds market is segmented by material core matrix, product type, therapeutic drug elution, clinical application focus, end user and region. Based on material core matrix, the market is segmented into Polymer-Based Vascular Scaffolds and Metal-Based Vascular Scaffolds. Based on product type, the market is segmented into Synthetic Scaffolds and Biological Scaffolds. Based on therapeutic drug elution, the market is segmented into Sirolimus and its Analogues, Paclitaxel-Coated Scaffolds and Others. Based on clinical application focus, the market is segmented into Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD) and Others. Based on end user, the market is segmented into Hospitals & Cardiac Centers and Ambulatory Surgical Centers (ASCs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Sirolimus and its analogues segment leads because the drug’s potent antiproliferative effect effectively mitigates neointimal hyperplasia, a primary cause of scaffold restenosis. Its molecular profile enables sustained release from bioresorbable matrices, maintaining therapeutic concentrations throughout the critical healing window. Clinicians value the proven safety record and reduced thrombogenic risk, driving preferential selection in complex coronary interventions. Continuous formulation refinements further improve drug‑polymer interactions, reinforcing its central role in scaffold performance.
Meanwhile, paclitaxel-coated scaffolds are emerging as the key high‑growth area because formulation techniques enable drug deposition on bioresorbable platforms, expanding applicability to lesions where sirolimus may be less optimal. Growing evidence of efficacy in patient cohorts spurs physician interest, while regulatory pathways for drug‑eluting designs accelerate market entry and adoption.
Coronary artery disease focus stands out because the majority of bioresorbable scaffold development aligns with the pathophysiology of atherosclerotic lesions within coronary vessels, where temporary support and vessel restoration provide clinical benefit. The high prevalence of CAD drives procedural volume, encouraging investment in scaffold optimization for arterial compliance and lesion coverage. Physicians prioritize evidence‑based outcomes in coronary settings, reinforcing demand for resorbable technologies that address restenosis while preserving vessel integrity.
On the other hand, peripheral artery disease applications are witnessing expansion because engineers are adapting bioresorbable scaffolds to accommodate larger vessel sizes and dynamics, opening therapeutic avenues beyond coronary interventions. Growing evidence of safety in peripheral vessels stimulates physician interest, and regulatory encouragement for revascularization options accelerates adoption, broadening market reach.
To get detailed segments analysis, Request a Free Sample Report
North America leads due to a combination of mature cardiovascular care networks, extensive clinical research capacity, and integrated payer systems that support innovative therapies. Hospitals and interventional cardiology centers benefit from deep expertise in advanced device implantation, fostering rapid uptake of bioresorbable technologies. Strong collaborations between academic institutions and device manufacturers accelerate product development and regulatory approvals. Reimbursement frameworks that recognize the long‑term clinical benefits of scaffold resorption further encourage adoption. Additionally, high patient awareness and demand for therapies that reduce long‑term foreign‑body complications reinforce market momentum, positioning the region as a benchmark for clinical outcomes and procedural standards.
Bioresorbable Coronary Scaffolds Market in the United States is propelled by leading academic hospitals that serve as early adopters and training hubs for interventionalists. Robust venture capital support fuels domestic innovation, while collaborative trials with global manufacturers refine product pipelines. Health system procurement processes that emphasize value‑based care align with the scaffold’s promise of reduced lifelong device burden, encouraging widespread institutional acceptance.
Bioresorbable Coronary Scaffolds Market in Canada benefits from a publicly funded healthcare model that prioritizes cost‑effective, patient‑centred solutions. Provincial health authorities actively evaluate emerging technologies, creating pathways for timely reimbursement. Multicenter research networks across major academic centres generate real‑world evidence that supports clinical confidence. The country’s strong regulatory alignment with international standards simplifies market entry for innovative scaffold platforms.
Europe’s expansion is driven by cohesive regulatory harmonization that streamlines product approval across multiple member states, encouraging manufacturers to focus on the region. Health systems emphasize outcomes that reduce long‑term procedural costs, creating a receptive environment for devices that dissolve after vessel healing. Collaborative clinical research consortia across leading cardiology centres generate robust evidence, reinforcing physician confidence. Moreover, a growing emphasis on patient quality of life and reduced dependency on long‑term antiplatelet therapy aligns with the therapeutic advantages of bioresorbable scaffolds, positioning Europe as a hub for adoption and innovation.
Bioresorbable Coronary Scaffolds Market in Germany is anchored by a dense network of specialized cardiovascular clinics that prioritize cutting‑edge interventions. Strong government‑backed research institutes partner with industry to advance scaffold design and procedural techniques. Reimbursement policies that reward long‑term health economic benefits support broader institutional uptake, while continuous professional education ensures interventionalists remain proficient with evolving technologies.
Bioresorbable Coronary Scaffolds Market in the United Kingdom experiences accelerated growth through active engagement of national health authorities in outcome‑based assessments. Leading academic hospitals serve as trial sites, generating pivotal clinical data that influence practice guidelines. The National Health Service’s focus on innovative yet cost‑conscious therapies creates a supportive environment for adopting scaffold solutions that promise reduced lifelong device dependence.
Bioresorbable Coronary Scaffolds Market in France is emerging as a focal point for translational research collaborations between university hospitals and biotech firms. Health technology assessment bodies evaluate long‑term clinical benefits, facilitating reimbursement pathways for promising scaffold products. Physician societies advocate for integrating resorbable technologies into standard care protocols, driving gradual but steady market penetration.
Asia Pacific is strengthening its position through strategic investments in medical infrastructure and a surge in domestic innovation. Countries are establishing dedicated cardiovascular research centers that focus on the unique anatomical and demographic considerations of the region, fostering tailored scaffold designs. Growing awareness of the benefits of avoiding permanent metallic implants resonates with patient populations seeking minimally invasive solutions. Collaborative frameworks between government health agencies and industry accelerate regulatory pathways, while expanding private hospital networks increase procedural capacity. Together, these factors create a dynamic ecosystem that enhances adoption and encourages local manufacturing capabilities.
Bioresorbable Coronary Scaffolds Market in Japan benefits from a longstanding tradition of precision medical engineering and a health system that values evidence‑based adoption. National guidelines endorse therapies that reduce long‑term complications, aligning with scaffold objectives. Leading cardiac centres conduct large‑scale clinical programs that generate robust data, influencing practitioner confidence and supporting broader market entry.
Bioresorbable Coronary Scaffolds Market in South Korea advances through strong governmental support for medical device innovation and a rapid diffusion of new technologies within its hospital network. Academic institutions collaborate closely with manufacturers to refine scaffold materials suited to local patient profiles. Reimbursement schemes that reward long‑term health improvements facilitate acceptance among clinicians and patients alike.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Adoption of Minimally Invasive Procedures
Advancements in Scaffold Material Technology
High Manufacturing Costs and Complexity
Regulatory Uncertainty and Approval Delays
Request Free Customization of this report to help us to meet your business objectives.
I’m unable to provide the requested content due to insufficient information.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the market is propelled primarily by the increasing adoption of minimally invasive procedures, while high manufacturing costs and complexity act as a restraint. North America emerges as the dominating region, supported by mature cardiovascular networks and favorable reimbursement. The polymer‑based vascular scaffold segment leads the market, reflecting clinician preference for resorbable polymers. A second driver is the rapid advancement in scaffold material technology, which delivers thinner struts and better degradation control, boosting physician confidence. Together, these forces shape a rapidly expanding market despite cost challenges, with North America and polymer‑based scaffolds anchoring growth globally in the coming years.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.05 Billion |
| Market size value in 2033 | USD 5.75 Billion |
| Growth Rate | 20.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Bioresorbable Coronary Scaffolds Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bioresorbable Coronary Scaffolds Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bioresorbable Coronary Scaffolds Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Bioresorbable Coronary Scaffolds Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
